シスプラチンとEGFR阻害剤を用いた治療

Japanese Patent JP2008501654

A

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and cisplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and cisplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

WO/2024/059205	TREATING PKU WITH SPIRO-SUBSTITUTED AND OTHER PIPERIDINE INHIBITORS OF SLC6A19 FUNCTION
WO/2019/178248	INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE
JPS63258814	MEDICINAL COMPOSITION FOR TREATING NAIL MYCOTIC INFECTION BY NITRIC ACID MICONAZOLE OR NITRIC ACID ECONAZOLE

Higgins, Bryan
Kolinsky, Kennis

JP2007513819A

January 24, 2008

May 27, 2005

Click for automatic bibliography generation  

F. HOFFMANN-LA ROCHE AKTIENGESELLSCHAFT

A61K31/17; A61K31/196; A61K31/255; A61K31/337; A61K31/407; A61K31/4164; A61K31/4706; A61K31/475; A61K31/496; A61K31/513; A61K31/517; A61K31/519; A61K31/52; A61K31/522; A61K31/525; A61K31/53; A61K31/5377; A61K31/573; A61K31/675; A61K31/7008; A61K31/704; A61K31/7048; A61K31/7068; A61K33/242; A61K33/243; A61K38/00; A61K38/43; A61K38/50; A61K45/00; A61P35/00

JP2003523949A	2003-08-12
JP2007501238A	2007-01-25

Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe

Previous Patent: アミノ−アルコキシ−ヘプタン酸アルキルエステルの合成

Next Patent: メロキシカム含有組成物